Skip to main content

FDA recall, , Moderate risk

Amneal PEMRYDI RTU (Pemetrexed Injection)

PEMRYDI RTU (pemetrexed injection) has a discolored solution, which can be green to dark green.

What happened

Shilpa Medicare Limited, of Jadcherla, Mahabubnagar District, India, recalled Pemrydi RTU (pemetrexed injection) because of a discolored solution. The firm received market complaints reporting green to dark green discoloration in certain vials. The recall, which began July 29, 2026, covers the 500 mg/50 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) single-dose vials, distributed nationwide in the USA.

The product was manufactured by Zydus Lifesciences Limited, Ahmedabad, India, and distributed by Amneal Pharmaceuticals LC, Bridgewater, NY 08807.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

2 products

Match the lot code and NDC listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Pemrydi RTU(pemetrexed injection)

    Strength
    500 mg
    NDC
    • 70121-2461-1
    Lot code
    • PA00047A
  2. Pemrydi RTU (pemetrexed injection)

    Strength
    100 mg
    NDC
    • 70121-2453-1
    Lot code
    • PA00050A

Recall details

Company began the recall
Sold in

Nationwide in the USA.

Company
Shilpa Medicare LimitedJadcherla, Mahabubnagar District, India
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
99530
Recall numbers
D-0764-2026 to D-0765-2026

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)